나이벡

138610KOSDAQ의료용품 및 기타 의약 관련제품 제조업

46.0 / 100

Reference Date: 2026-04-13

Financial Score11.5 / 40

News Sentiment20.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Declined 13.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Nabix operates in the fields of bio-regenerative materials, peptide pharmaceuticals, and oral health products, holding global certifications such as FDA, CE, and NMPA, and selling products worldwide. The company is focusing on expanding its global market through the commercialization of new products like PeptiCol EZgraft and obtaining European MDR certification, while also developing early diagnosis kits and treatments for periodontal diseases.

Number of Employees

93people

Average Salary

59.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

61.90Industry Average 19.890.0Point

3.1x industry avg (risky)

PBR

6.39Industry Average 1.620.0Point

3.9x industry avg (risky)

ROE

11.89Industry Average -4.893.5Point

Well below industry avg

Debt Ratio

11.70Industry Average 8.882.0Point

Higher than industry avg (caution)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲44.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 0Negative 0Average Sentiment Score 90

Positive
나이벡, 흑자전환 성공…지난해 영업이익 50억원 달성
나이벡은 지난해 미국 제약·바이오 기업과의 기술이전 계약에 따른 선급금 반영으로 매출 327억원, 영업이익 50억원을 기록하며 흑자전환에 성공했습니다.
Positive
나이벡, EU-GMP QP 실사 완료…유럽 임상 의약품 공급 기반 확보
나이벡은 유럽 임상시험용 의약품 공급을 위한 EU-GMP QP 현장 실사를 완료하여 유럽 임상 의약품 생산 및 공급 기반을 확보하고 펩타이드 CDMO 사업 확장을 위한 인프라를 구축했습니다.
Positive
나이벡, 콜라겐 기반 재생소재 ‘리제노머’ 유럽 MDR 인증
나이벡은 콜라겐 기반 조직 재생용 바이오 소재 제품 '리제노머'가 유럽 의료기기 규정(MDR) 인증 심사를 통과하여 유럽 시장 진출을 위한 중요한 발판을 마련했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 25,750Won52-week high 52,30052-week low 19,310

1-month return1.0Point

1m -13.88% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식매수선택권부여에관한신고2026-03-30
Neutral정기주주총회결과2026-03-30
Neutral감사보고서제출2026-03-20
Neutral사업보고서 (2025.12)2026-03-20
Neutral[첨부정정]의결권대리행사권유참고서류2026-03-16